CooperVision Completes Enrollment for Clinical Study of Pediatric Myopia Control

ROCHESTER, N.Y.—CooperVision announced it has completed enrollment of its global MiSight 1 day post-approval clinical studies (PAS) in the U.S. and China, described by the company as a milestone in real-world evidence generation for pediatric myopia control. Together, these studies represent the longest international clinical evidence program ever undertaken for soft contact lens-based myopia control intervention in children, according to the company, including both randomized controlled efficacy trials and large-scale safety registries. The combined PAS programs span more than 100 clinical sites and include over 3,000 children.